Bristol Myers Squibb chose the Leiden Bio Science Park as the European location for a new CAR T cell therapy facility. With this new facility, we are investing in the expansion of our global network to bring cell therapy closer to patients with blood cancers in Europe.
This production centre is our first European site and will be our fifth facility worldwide working on the development of cell therapy. The facility will be equipped with the latest technology and manufacturing equipment. The design and planning of the site is currently ongoing. Construction work will start in autumn 2021 and the site is expected to be completed and operational by the end of 2024.
With this new production centre, we are contributing to the growing role of the Netherlands as an international leader in the field of CAR T cell therapy.